锌作为人体必需的微量元素之一，被称为"生命之花"，参与人体200多种酶的合成与激活，贯穿生长发 育、免疫调节、物质代谢、生殖健康等全部生理过程。世界卫生组织（WHO）1973年已确认锌为人体 必需微量元素并制定膳食标准，锌缺乏可引发生长迟缓、免疫力下降、生殖功能异常等问题。《中国居 民营养与慢性病状况报告（2025年）》显示，我国3岁以下婴幼儿锌缺乏发生率达18.6%，学龄前儿童 锌摄入不足率22.3%，锌缺乏已成为影响居民尤其是儿童生长发育的主要营养问题。 一、核心认知：药字号与食字号的本质区别 药字号与食字号补锌产品并非简单"药品与食品"的差异，在审批、生产、功效、安全等方面存在根本区 别。结合国家药品监督管理局（NMPA）及卫生健康委员会相关规定，明确：对于确诊缺锌或有明确缺 锌风险的人群，药字号产品是临床首选，食字号仅可作为健康人群日常轻微补充，不可替代药字号用于 治疗。 （一）药字号补锌产品（临床首选，疗效确切） 药字号产品（批准文号为"国药准字+字母+8位数字"）属于药品范畴，需经NMPA严苛审批，完成Ⅰ-Ⅲ 期临床试验，证实疗效与安全性后才可上市，核心特点如下： 1. 审批标准：需提交完整临床研 ...

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small-cap stocks with huge growth potential. On February 18, Evercore ISI resumed coverage of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) with a Buy rating and set a price target of $17.00. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) also received a rating update from Bank of America Securities on January 27, which reaffirmed a Buy rating on the stock with a price target of $15. Cantor Fitzgerald Sees Deal Activity and Pipeline Progress as Key ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total revenue for the year ended December 31, 2025, was $944 million compared to $705 in the previous year, considerably surpassing expectations due to continued commercial success. The company also earned substantial R&D revenue, including a $280 million upfront payment for the glo ...

Core Viewpoint - Corcept Therapeutics is facing a class action lawsuit due to alleged misrepresentations regarding the approval process of its drug relacorilant, which has led to significant stock price declines following negative FDA feedback [4][5][6]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Corcept securities between October 31, 2024, and December 31, 2025, with a deadline for filing a lead plaintiff motion set for April 21, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Company Overview - Corcept Therapeutics specializes in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a key product candidate for treating hypercortisolism [3]. Group 3: Allegations Against Corcept - The lawsuit claims that Corcept misled investors by stating that the relacorilant New Drug Application (NDA) was well-supported and nearing approval, despite known concerns from the FDA regarding clinical evidence [4]. - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating that additional evidence was needed for a favorable benefit-risk assessment, resulting in a stock price drop of over 50% [5]. - A redacted copy of the CRL published by the FDA on January 30, 2026, highlighted concerns about the adequacy of clinical studies submitted, and prior warnings from the FDA about potential review issues were noted [6].

Several established products saw sizable declines. Peters said glucagon sales fell 45% to $14.1 million , citing increased competition and a market shift toward ready-to-use products such as BAQSIMI. Epinephrine sales declined 9% to $17.1 million due to increased competition for the company’s epinephrine multi-dose vial products, partially offset by higher unit volumes for epinephrine pre-filled syringes amid supplier shortages during the quarter.Newer products also began contributing, including $4.4 millio ...

On February 17, 2026, ICAHN CARL C disclosed a buy of  Icahn Enterprises (NASDAQ:IEP). What happened According to a recent SEC filing, ICAHN CARL C increased its stake in Icahn Enterprises by 30,467,595 shares during the fourth quarter. The estimated value of this purchase was $245.63 million, calculated using the average closing price over the quarter. As a result, the fund’s quarter-end position in IEP rose to 549,400,539 shares, with the total value of the stake decreasing by $221.44 million compared ...

Indivior PLC Q4 2025 Earnings Call Summary - Moby Strategic Transition and Operational Execution Completed 'Generate Momentum' phase in 2025, transitioning to 'Accelerate' phase in 2026 to drive SUBLOCADE dispense unit growth and margin expansion. Attributed 2025 performance to improved commercial execution and record SUBLOCADE net revenue of $856 million, a 13% year-over-year increase. Simplified the organizational structure to establish a go-forward operating model designed to cap 2026 operating e ...

Management is intentionally shifting the business model toward Pharma Manufacturer Solutions (rebranded as Pharma Direct) to capture the growing trend of direct-to-consumer pharmaceutical commercialization. The core Rx Marketplace faced headwinds from the Rite Aid bankruptcy and lower volumes in specific Integrated Savings Program partnerships, totaling an approximately $35 million-$40 million impact in 2025. Strategic focus has moved toward high-intent, condition-specific subscriptions in areas like ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

麓鹏制药董事长兼CEO谭芬来博士。 工作中的谭芬来博士。 在中国创新药发展版图中，创新药老兵谭芬来博士是一个独特的存在。 七年前，在由其主导临床研发的中国首个小分子靶向抗癌药埃克替尼(凯美纳)惠及数十万患者、首个 ALK靶点创新药恩沙替尼蓄势待发之时，他却选择卸下荣光，创立了一家连名字都直抒高远之志的创 新药企业——麓鹏制药。 七年后的今天，他带领团队交出了一份份令人满意的阶段性成绩单：全球首个且唯一共价兼非共价布鲁 顿酪氨酸激酶(BTK)抑制剂洛布替尼，成为中国首个被认定为弥漫大B细胞淋巴瘤(DLBCL)突破性疗法 的BTK抑制剂，并已启动关键性注册Ⅱ期临床研究；针对复发或难治性套细胞淋巴瘤(R/R MCL)的新药 上市申请(NDA)，获国家药品监督管理局药品审评中心(CDE)受理并纳入优先审评程序；启动治疗复发 或难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(R/R CLL/SLL)的全球三期头对头临床试验，正面挑战国 际制药巨头礼来公司的第三代BTK抑制剂匹妥布替尼，直面全球化竞争。 从杭州西子湖畔到广州黄埔科学城，谭芬来完成的不只是一次地理上的回归，更是一场从"创中国首 个"到"创全球首个"的信念升级。在 ...